{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:20:43Z","timestamp":1793496043039,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.parkreldis.2016.04.023","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T15:27:30Z","timestamp":1461943650000},"page":"35-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6531-7955","authenticated-orcid":false,"given":"Robbert W.K.","family":"Borgemeester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teus","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2016.04.023_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","article-title":"Epidemiology of psychosis in Parkinson's disease","volume":"289","author":"F\u00e9nelon","year":"2010","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib2","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1212\/WNL.0b013e3181fd6158","article-title":"Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study","volume":"75","author":"Goetz","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib3","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1001\/jama.1971.03190260031009","article-title":"Psychiatric side effects of levodopa in man","volume":"218","author":"Goodwin","year":"1971","journal-title":"JAMA"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2377-13-145","article-title":"Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study","volume":"13","author":"Sawada","year":"2013","journal-title":"BMC Neurol."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.parkreldis.2008.11.013","article-title":"Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania","volume":"15","author":"Dotchin","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/01.WNL.0000103444.45882.D8","article-title":"Ophthalmologic features of Parkinson's disease","volume":"62","author":"Biousse","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000191325.31068.c4","article-title":"Hallucinations in Parkinson disease in the prelevodopa era","volume":"66","author":"F\u00e9nelon","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.26432","article-title":"Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase","volume":"31","author":"Pagonabarraga","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1353-8020(97)00009-6","article-title":"Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment","volume":"3","author":"Ellis","year":"1997","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/jnnp.52.4.544","article-title":"Subcutaneous apomorphine in Parkinson's disease","volume":"52","author":"Pollak","year":"1989","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/jnnp.54.4.372","article-title":"Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment","volume":"54","author":"Ray-Chaudhuri","year":"1991","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.parkreldis.2009.05.006","article-title":"Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations","volume":"16","author":"Van Laar","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1017\/S0140525X05000130","article-title":"Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations","volume":"28","author":"Collerton","year":"2005","journal-title":"Behav. Brain Sci."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib14","series-title":"The Neuroscience of Visual Hallucinations","first-page":"151","article-title":"Imaging in visual hallucinations","author":"Meppelink","year":"2015"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.parkreldis.2015.04.005","article-title":"Structural and functional neuroimaging in patients with Parkinson's disease and visual hallucinations: a critical review","volume":"21","author":"Lenka","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2012.07.012","article-title":"Foveal vision is impaired in Parkinson's disease","volume":"19","author":"Bodis-Wollner","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib17","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/brain\/awp068","article-title":"The retina in Parkinson's disease","volume":"132","author":"Archibald","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib18","series-title":"The Neuroscience of Visual Hallucinations","first-page":"121","article-title":"Hallucinogenic mechanisms: pathological and pharmacological insights","author":"Lewis","year":"2015"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib19","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/ana.24182","article-title":"Alpha-synuclein in the inner retina in Parkinson disease","volume":"75","author":"Bodis-Wollner","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib20","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1136\/jnnp-2012-303391","article-title":"Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson's disease","author":"Shin","year":"2012","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib21","first-page":"147","article-title":"The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study","volume":"259","author":"Janzen","year":"2012","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib22","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/NEN.0000000000000014","article-title":"Pedunculopontine cholinergic cell loss in hallucinating Parkinson disease patients but not in dementia with Lewy bodies patients","volume":"72","author":"Hepp","year":"2013","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib23","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.npp.1301461","article-title":"Selective effects of cholinergic modulation on task performance during selective attention","volume":"33","author":"Furey","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.bbr.2010.11.033","article-title":"Acetylcholine and attention","volume":"221","author":"Klinkenberg","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0028-3932(88)90004-8","article-title":"Modelling dementia: effects of scopolamine on memory and attention","volume":"26","author":"Broks","year":"1988","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib26","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/archinte.161.8.1099","article-title":"Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients","volume":"161","author":"Han","year":"2001","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/brain\/awm299","article-title":"Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health","volume":"131","author":"Bentley","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1460-9568.2011.07749.x","article-title":"Cholinergic control of cortical network interactions enables feedback-mediated attentional modulation","volume":"34","author":"Deco","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib29","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.conb.2006.09.002","article-title":"The role of acetylcholine in learning and memory","volume":"16","author":"Hasselmo","year":"2006","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrneurol.2009.62","article-title":"Hallucinations in Parkinson disease","volume":"5","author":"Diederich","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib31","first-page":"242","article-title":"Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia","volume":"253","author":"Bohnen","year":"2006","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib32","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1212\/01.wnl.0000191154.78131.f6","article-title":"Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways","volume":"65","author":"Hilker","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib33","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","article-title":"Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease","volume":"21","author":"Burn","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib34","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1471-4159.1990.tb03162.x","article-title":"Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia","volume":"55","author":"Perry","year":"1990","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib35","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/11319860-000000000-00000","article-title":"Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials","volume":"33","author":"Kulisevsky","year":"2010","journal-title":"Drug Saf."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib36","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jocn.2013.10.041","article-title":"Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson's disease","volume":"21","author":"Zhou","year":"2014","journal-title":"J.\u00a0Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib37","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/WNL.50.2.515","article-title":"Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations","volume":"50","author":"Goetz","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib38","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/mds.22063","article-title":"Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study","volume":"23","author":"Garc\u00eda Ruiz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3233\/JPD-2011-11037","article-title":"Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect","volume":"1","author":"Martinez-Martin","year":"2011","journal-title":"J.\u00a0Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.26067","article-title":"EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease","volume":"30","author":"Martinez-Martin","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2015.11.013","article-title":"Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients","volume":"23","author":"Borgemeester","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF01250567","article-title":"Effect of apomorphine on schizophrenic symptoms","volume":"40","author":"Smith","year":"1977","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1126\/science.347574","article-title":"Schizophrenic symptoms improve with apomorphine","volume":"200","author":"Tamminga","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib44","first-page":"1309","article-title":"The use of dopamine agonists in the treatment of schizophrenia","volume":"20","author":"Corsini","year":"1981","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib45","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.parkreldis.2013.08.012","article-title":"Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease","volume":"19","author":"Todorova","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib46","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0140-6736(89)90116-5","article-title":"Side-effects of subcutaneous apomorphine in Parkinson's disease","volume":"1","author":"Ruggieri","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib47","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/pgmj.70.823.344","article-title":"Subcutaneous apomorphine infusion in Parkinson's disease: does it have a role?","volume":"70","author":"Muhiddin","year":"1994","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/jnnp.53.2.96","article-title":"Subcutaneous apomorphine in the treatment of Parkinson's disease","volume":"53","author":"Frankel","year":"1990","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2125.1991.tb03950.x","article-title":"Selective effects of low doses of apomorphine on spatiotemporal contrast sensitivity in healthy volunteers: a double-blind placebo-controlled study","volume":"32","author":"Blin","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib50","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/0014-2999(90)92874-I","article-title":"Human spatiotemporal contrast sensitivity: dopaminergic induced variations","volume":"183","author":"Mestre","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib51","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/WNF.0b013e3181a6a92b","article-title":"The effects of apomorphine on visual perception in patients with Parkinson disease and visual hallucinations: a pilot study","volume":"32","author":"Geerligs","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib52","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1353-8020(01)00046-3","article-title":"Apomorphine delays simple reaction time in Parkinsonian patients","volume":"8","author":"M\u00fcller","year":"2002","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib53","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2174\/1573406410666131229150746","article-title":"Essential structural features of novel antischizophrenic drugs: a review","volume":"10","author":"Nematollahi","year":"2014","journal-title":"Med. Chem."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib54","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/mds.10281","article-title":"Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients","volume":"17","author":"Manson","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib55","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.bmcl.2014.02.066","article-title":"Evaluation of structural effects on 5-HT2A receptor antagonism by aporphines: identification of a new aporphine with 5-HT2A antagonist activity","volume":"24","author":"Ponnala","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib56","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H","article-title":"Apomorphine: an underutilized therapy for Parkinson's disease","volume":"15","author":"Poewe","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib57","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/cbdd.12069","article-title":"Structure-based identification of aporphines with selective 5-HT2A receptor-binding activity","volume":"81","author":"Munusamy","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib58","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes","volume":"303","author":"Millan","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib59","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/jpet.102.039875","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)\/alpha(2)-adrenoceptor","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib60","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.102.039883","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib61","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1523\/JNEUROSCI.20-03-01208.2000","article-title":"Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex","volume":"20","author":"Granon","year":"2000","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib62","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/sj.npp.1300490","article-title":"Dopaminergic modulation of visual attention and working memory in the rodent prefrontal cortex","volume":"29","author":"Chudasama","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib63","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.biopsych.2011.03.028","article-title":"Inverted-U-shaped dopamine actions on human working memory and cognitive control","volume":"69","author":"Cools","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib64","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/376572a0","article-title":"Modulation of memory fields by dopamine D1 receptors in prefrontal cortex","volume":"376","author":"Williams","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib65","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/mds.20118","article-title":"Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism","volume":"19","author":"Foltynie","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib66","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/brain\/124.6.1125","article-title":"Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex","volume":"124","author":"Kaasinen","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib67","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1093\/brain\/awp245","article-title":"The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort","volume":"132","author":"Williams-Gray","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib68","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/mds.25687","article-title":"Dopamine overdose hypothesis: evidence and clinical implications","volume":"28","author":"Vaillancourt","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib69","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1523\/JNEUROSCI.0774-07.2007","article-title":"Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease","volume":"27","author":"Williams-Gray","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib70","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/jcbfm.2011.194","article-title":"Functional significance of central D1 receptors in cognition: beyond working memory","volume":"32","author":"Takahashi","year":"2012","journal-title":"J.\u00a0Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1471-4159.2002.01149.x","article-title":"Circadian rhythmicity in dopamine content of mammalian retina: role of the photoreceptors","volume":"83","author":"Doyle","year":"2002","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib72","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.neuron.2008.07.017","article-title":"The circadian clock in the retina controls rod-cone coupling","volume":"59","author":"Ribelayga","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib73","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1073\/pnas.95.2.735","article-title":"5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites","volume":"95","author":"Jakab","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib74","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in Parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib75","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","article-title":"Increased 5-HT2A receptors in the temporal cortex of Parkinsonian patients with visual hallucinations","volume":"25","author":"Huot","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib76","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1097\/00001756-200408260-00023","article-title":"Psilocybin impairs high-level but not low-level motion perception","volume":"15","author":"Carter","year":"2004","journal-title":"Neuroreport"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib77","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1162\/089892905774597191","article-title":"Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors","volume":"17","author":"Carter","year":"2005","journal-title":"J.\u00a0Cogn. Neurosci."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib78","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib79","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.biopsych.2010.10.002","article-title":"The 5-HT2A\/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations","volume":"69","author":"Kometer","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib80","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0361-9230(01)00646-3","article-title":"A\u00a0systems model of altered consciousness: integrating natural and drug-induced psychoses","volume":"56","author":"Vollenweider","year":"2001","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib81","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/mds.22258","article-title":"Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study","volume":"23","author":"Ram\u00edrez-Ruiz","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib82","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1212\/01.WNL.0000141853.27081.BD","article-title":"Altered cortical visual processing in PD with hallucinations: an fMRI study","volume":"63","author":"Stebbins","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib83","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/npp.2011.228","article-title":"Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers","volume":"37","author":"Quednow","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib84","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.parkreldis.2016.04.023_bib85","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2016.04.023_bib86","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00210-008-0341-4","article-title":"The in\u00a0vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease","volume":"379","author":"Scheller","year":"2009","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802016301274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802016301274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T07:14:53Z","timestamp":1600499693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802016301274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":86,"alternative-id":["S1353802016301274"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.04.023","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}